A 2021 cross-sectional study in the Journal of Bone and Mineral Research found that approximately 70% of adults in industrialized nations have subclinical vitamin K2 insufficiency — enough to compromise carboxylation of bone and vascular proteins while producing no classical deficiency symptoms detectable on routine blood panels. This silent insufficiency is increasingly linked to accelerated vascular calcification and reduced bone mineral density, conditions that interact and amplify each other in aging adults.
Vitamin K2 sits at the intersection of skeletal and cardiovascular health through a mechanism that was only elucidated in the 1990s: its role as a cofactor for gamma-carboxylation of specific proteins that direct calcium to bone and away from arterial walls. Understanding this mechanism explains why K2 deficiency, K2 supplementation, and K2-drug interactions have clinical significance well beyond simple coagulation pathways. Related: Vitamin C and Collagen: Skin Health Guide
Understanding Vitamin K2: MK-4 vs MK-7
The vitamin K family consists of phylloquinone (K1, found abundantly in leafy vegetables and primarily active in hepatic coagulation factor synthesis) and a series of menaquinones (K2), differentiated by the length of their isoprene side chain. The two most clinically significant K2 forms are MK-4 (menaquinone-4) and MK-7 (menaquinone-7).
MK-4 is synthesized endogenously from K1 via tissue-specific conversion, particularly in the brain, testes, and pancreas. It has a very short half-life of 1–2 hours in serum, requiring multiple daily dosing for sustained tissue delivery. MK-7, derived primarily from bacterial fermentation (as in the traditional Japanese food natto), has a serum half-life of 72 hours — allowing once-daily dosing and producing substantially more stable elevations in circulating K2 levels.
A key pharmacokinetic study by Schurgers and Vermeer (2000, Haemostasis) compared MK-4 and MK-7 supplementation in healthy volunteers and found that MK-7 at 45 mcg/day produced circulating MK-7 levels 10-fold higher than MK-4 at 1,000 mcg/day, and was significantly more effective at carboxylating osteocalcin — the primary bone protein requiring K2 as a cofactor. This pharmacokinetic advantage has shifted most modern K2 research and clinical supplementation toward MK-7.
How K2 Supports Bone Health: Osteocalcin and Beyond
The primary mechanism linking vitamin K2 to bone health is the gamma-carboxylation of osteocalcin, a non-collagenous protein produced exclusively by osteoblasts. Carboxylated osteocalcin (cOC) binds calcium ions and hydroxyapatite crystals, anchoring them in the bone matrix to increase mineral density and bone stiffness. Undercarboxylated osteocalcin (ucOC) — which accumulates with K2 insufficiency — fails to bind hydroxyapatite and instead circulates in blood, serving as a sensitive marker of K2 status.
Clinical evidence is substantial. A 3-year RCT by Knapen et al. (2013, Osteoporosis International) randomized 244 postmenopausal women to MK-7 (180 mcg/day) or placebo. The MK-7 group showed significantly less age-related loss of lumbar spine bone mineral content and bone mineral density, and improved vertebral bone geometry (higher stiffness index). Crucially, this was achieved in women not selected for osteoporosis — suggesting K2 supports bone maintenance across the general aging population, not only as treatment for established deficiency.
Beyond osteocalcin, K2 carboxylates Gla-osteocalcin and periostin in periosteal bone, modulates RANKL/OPG signaling to reduce osteoclast activity, and appears to support growth plate regulation through chondrocyte differentiation — mechanisms that extend K2's bone relevance beyond simple mineralization support.
| K2-dependent Protein | Location | Function when Carboxylated | Consequence of Under-carboxylation |
|---|---|---|---|
| Osteocalcin (OC) | Bone matrix | Binds Ca²⁺ and hydroxyapatite | Reduced bone mineral density |
| Matrix Gla Protein (MGP) | Vascular smooth muscle, cartilage | Inhibits ectopic calcium deposition | Arterial calcification |
| Gas6 | Vascular endothelium | Regulates endothelial cell survival and NO production | Impaired vascular tone |
| Protein S | Liver, endothelium | Anticoagulant cofactor, complement regulation | Thrombotic risk (mild) |
Cardiovascular Protection: The MGP Connection
Matrix Gla Protein (MGP) is arguably the most important vitamin K2-dependent protein for cardiovascular health. MGP is produced by vascular smooth muscle cells and chondrocytes and, when fully carboxylated by K2, acts as one of the most potent inhibitors of soft-tissue and vascular calcification known in mammals. Luo et al. (1997, Nature) demonstrated that MGP-knockout mice spontaneously develop massive arterial calcification and die within 8 weeks of birth from arterial rupture — a direct and dramatic demonstration of MGP's vascular protective role.
In humans, circulating dephospho-uncarboxylated MGP (dp-ucMGP) is used as a validated biomarker of vascular K2 status. Higher dp-ucMGP (indicating more uncarboxylated, inactive MGP) is independently associated with increased coronary artery calcification scores, aortic stiffness, and cardiovascular event risk in prospective cohort studies. Critically, dp-ucMGP levels are elevated in patients taking vitamin K antagonist anticoagulants (warfarin), which block all K-dependent carboxylation reactions — a pharmacological confirmation that the K2-MGP axis is physiologically active in human vasculature.
A 3-year intervention study by Knapen et al. (2015, Thrombosis and Haemostasis) found that MK-7 supplementation (180 mcg/day) in postmenopausal women significantly reduced arterial stiffness assessed by carotid-femoral pulse wave velocity (CF-PWV) and reduced dp-ucMGP levels by 50%, suggesting meaningful carboxylation of vascular MGP. Subjects with highest baseline dp-ucMGP (most deficient) showed the greatest improvements.
Dietary Sources of Vitamin K2
The dietary landscape of vitamin K2 is narrower than that of K1. The richest source by orders of magnitude is natto — a Japanese fermented soybean product produced by Bacillus subtilis fermentation — which contains approximately 1,000–1,500 mcg MK-7 per 100 g serving. A single small serving of natto (30–50 g) provides several days' worth of K2 at therapeutic supplementation doses. However, natto's intense flavor and sticky texture limit its acceptance outside Japan.
Beyond natto, K2 food sources provide primarily MK-4 in modest amounts:
- Hard and fermented cheeses (Gouda, Brie, Emmental): 10–75 mcg MK-4 + MK-7 per 100 g, depending on aging and fermentation process
- Egg yolks: ~15 mcg MK-4 per 100 g
- Chicken liver and other organ meats: 10–30 mcg MK-4 per 100 g
- Butter and full-fat dairy from grass-fed animals: 5–20 mcg MK-4 per 100 g (significantly higher in grass-fed vs. grain-fed animals)
- Fermented sauerkraut and other lacto-fermented vegetables: variable MK-7, generally 1–10 mcg per 100 g depending on culture strains
For most people eating a Western diet, food sources alone are insufficient to achieve the 180 mcg MK-7/day levels shown to improve vascular and bone markers in clinical trials, making supplementation the primary route to therapeutic K2 intake.
Supplementation: Dosing, Timing, and Synergies
The evidence-based supplementation dose for MK-7 for bone and cardiovascular wellness is 90–360 mcg/day, with the most frequently studied doses in clinical trials being 90 mcg and 180 mcg. MK-7 is fat-soluble and should be taken with the largest meal of the day containing dietary fat to maximize absorption; lymphatic uptake of fat-soluble vitamins through chylomicrons is substantially higher with concurrent fat intake.
The K2-D3 synergy is clinically important. Vitamin D3 drives osteocalcin and MGP gene expression, increasing the production of these K2-dependent proteins. Without adequate K2 to carboxylate the proteins that D3 upregulates, D3 supplementation can paradoxically increase circulating ucOC and ucMGP — proteins that cannot bind calcium properly. This is the mechanistic basis for the clinical observation that high-dose D3 supplementation without K2 may accelerate vascular calcification in some individuals. Combining K2 (MK-7 90–180 mcg) with D3 (1,000–4,000 IU/day) is therefore both mechanistically logical and practically supported by the supplementation literature.
Individuals on vitamin K antagonist medications (warfarin, acenocoumarol) must consult their anticoagulation physician before supplementing K2, as even modest MK-7 supplementation can significantly alter INR values. MK-4 at doses below 1,500 mcg/day has less INR impact, but medical supervision remains essential.
NIR Photobiomodulation as a Complementary Wellness Tool
Near-infrared photobiomodulation at 630–850 nm has demonstrated independent effects on bone and vascular tissue in preclinical and early clinical research that are mechanistically complementary — not overlapping — with vitamin K2's carboxylation functions.
For bone: de Medeiros et al. (2021, Lasers in Medical Science) found that 808 nm NIR photobiomodulation stimulated osteoblast proliferation and increased bone mineral density in rodent models through Wnt/β-catenin and BMP-2 signaling — pathways independent of the vitamin K carboxylation axis. If these effects extend meaningfully to humans, NIR and K2 may support bone health through entirely separate and potentially additive mechanisms.
For circulation: NIR-mediated nitric oxide (NO) release from cytochrome c oxidase improves endothelial vasodilation and reduces resting vascular smooth muscle tone. MGP carboxylation reduces calcification of the arterial media. Together, they address complementary aspects of arterial wall health — one functional (vasomotor tone), one structural (calcium homeostasis in the arterial wall).
A practical daily integration: take MK-7 with the evening meal, and schedule a 10–15 minute NIR session targeting lumbar spine and major joints in the morning or post-exercise window, supporting both mitochondrial tissue energy and circulation in a structured wellness routine.
